Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Revolution Medicines

Tracked across 13 events · 1048 articles · First seen Apr 15, 2026 · Last active Sep 22, 2026

Sentiment
49
Attention
8
Events
13
Relationships
14
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 80
Regulatory
Impact: Revolution Medicines is the developer of daraxonrasib; the EMA phased review and FDA submission progress are key regulatory milestones that could lead to market approval and significant revenue.
Jul 07, 2026 · 7 articles
4 60
Business
Impact: Revolution Medicines expands its global reach through BeOne's regional infrastructure and receives milestone payments and royalties. It retains rights outside the licensed territories, including Japan and South Korea.
Aug 10, 2026 · 7 articles
7 90
Regulatory
Impact: Revolution Medicines received FDA approval for its lead drug daraxonrasib (Rasonque), a first-in-class RAS inhibitor. The approval is expected to drive substantial revenue growth, with analysts projecting up to $11.5 billion in annual sales, and the company's stock has risen 166% this year.
Aug 26, 2026 · 92 articles
4 70
Tech
The United States — Food and Drug Administration approved daraxonrasib, a first-of-its-kind daily pill for metastatic pancreatic cancer, sold by Revolution Medicines under the brand name Rasonque. The drug blocks mutated KRAS proteins that drive…
Impact: Secures first approval and commercial launch of daraxonrasib under the Rasonque brand at about $39,800 per month, validating its KRAS molecular glue platform and opening expansion into other cancers.
Aug 26, 2026 · 6 articles
7 90
Tech
Impact: Revolution Medicines developed daraxonrasib, the experimental drug that has shown significant promise in treating advanced pancreatic cancer, leading to increased attention and potential for market growth for the company.
May 29, 2026 · 74 articles
7 10
Regulatory
Impact: Revolution Medicines is the company that accused Erasca of patent infringement and trade secret misappropriation related to Erasca's ERAS-0015, claiming improper comparisons to its own drug candidate RMC-6236. This action has negatively impacted Erasca.
May 19, 2026 · 323 articles
4 40
Regulatory
Impact: Revolution Medicines is the competitor whose patent and trade secret claims against Erasca triggered the stock drop. The allegations could strengthen its competitive position in the RAS-targeting space.
Jun 11, 2026 · 193 articles
2 40
Tech
Impact: Revolution Medicines' daraxonrasib is referenced as a comparator with strong Phase 3 results. The comparison highlights the competitive landscape but does not directly impact its operations.
Aug 27, 2026 · 6 articles
6 75
Tech
Impact: Revolution Medicines>>> is developing daraxonrasib, a new drug targeting the RAS gene, which offers hope for patients to overcome resistance to standard treatments.
Jun 03, 2026 · 6 articles
2 60
Tech
Impact: The guideline highlights the potential of RAS inhibitors like daraxonrasib, which could expand the market for Revolution Medicines' drug and boost its stock.
Aug 13, 2026 · 6 articles
8 20
International
Impact: Revolution Medicines is the maker of daraxonrasib, an experimental pill showing promise for advanced pancreatic cancer, and plans to seek United States — Food and Drug Administration approval.
May 18, 2026 · 316 articles
1 0
Business
Impact: Revolution Medicines is mentioned as a current board seat for Borellini; not directly affected by this event.
Jul 13, 2026 · 6 articles
2 5
Business
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the…
Impact: Listed as an existing partnership partner of Iambic, with no new action in this event.
Sep 21, 2026 · 6 articles
Erasca patent plaintiff ↔ Revolution Medicines Revolution Medicines is actively pursuing a patent infringement and trade secret
Erasca patent defendant ↔ Revolution Medicines Erasca is currently defending against a patent infringement and trade secret mis
Kahn Swick & Foti ↔ Revolution Medicines
Hagens Berman ↔ Revolution Medicines
Kahn Swick & Foti ↔ Revolution Medicines
Hagens Berman ↔ Revolution Medicines
Rosen Law Firm ↔ Revolution Medicines
Rosen Law Firm ↔ Revolution Medicines
United States ↔ Revolution Medicines
United States ↔ Revolution Medicines
ERGEN INTELLIGENCE
Track Revolution Medicines live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.